TIGIT-TF tag mRNA-LNP

TIGIT (T cell immune receptor with Ig and ITIM domains) is an immune receptor of the Ig superfamily, encoded by the TIGIT gene. It is expressed on the surface of natural killer cells, Treg and T cells. TIGIT plays a key role in limiting adaptive and innate immunity by interacting with two ligands presented by antigen-presenting cells, namely CD155 and CD112. It can be thought of as an immune checkpoint. Like PD-1, TIGIT is overexpressed on tumor antigen-specific (TA-specific) CD8+ T cells and CD8+ tumor-infiltrating lymphocytes (TILs) in melanoma. Blockade of TIGIT and PD-1 resulted in increased cell proliferation, cytokine production, and degranulation of TA-specific CD8+ T cells and TIL CD8+ T cells. Anti-TIGIT antibodies are currently being evaluated in human clinical trials alone or in combination with nivolumab in various locally advanced solid tumors. Nivolumab is a monoclonal antibody that binds to the PD-1 protein on the surface of T cells.
This product is designed as a tool for the delivery and expression of human TF tagged TIGIT mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of TIGIT-TF mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The TIGIT-TF fusion protein is approximately 29 kD, consisting of mature TIGIT (244 amino acids) and a C-terminal TF tag (15 amino acids). The GenPept accession number for TIGIT is NP_776160.